Alivus Life Sciences Limited has informed the Exchange regarding a press release dated May 14, 2026, titled "Press Release of the Company for the fourth quarter and year ended March 31, 2026.".
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences (formerly Glenmark Life Sciences) reported strong FY26 results with revenue from operations of Rs. 25,518 Mn, up 6.9% YoY. EBITDA grew 19.6% to Rs. 8,577 Mn with margins expanding 360 bps to 33.6%, exceeding the company's guided range of 30-32%. PAT stood at Rs. 5,645 Mn, growing 16.2% YoY with margins at 22.1%, up 180 bps. The company generated strong free cash flow of Rs. 2,590 Mn and ended with cash and equivalents of Rs. 7,824 Mn, maintaining a debt-free balance sheet. The CDMO business delivered an 18% YoY turnaround in H2, while GPL business de-grew 4.9%.
Strong operational performance with significant margin expansion signals improved profitability and cost efficiency. The company's debt-free status and robust cash generation provide financial flexibility for growth investments in new R&D facilities and expanded manufacturing capacity.